bluebird bio, Inc. Common Stock
BLUE US09609G1004
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -78% | -35% | -80% | 467% | 6% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Colvin Richard A CMO |
3.92 USD |
584 Sold |
2,289 USD |
03/03/2025 | 03/03/2025 |
| Klima Thomas J O |
3.92 USD |
500 Sold |
1,960 USD |
03/03/2025 | 03/03/2025 |
| Obenshain Andrew CEO |
3.92 USD |
921 Sold |
3,610 USD |
03/03/2025 | 03/03/2025 |
| Obenshain Andrew CEO |
7.39 USD |
86 Sold |
636 USD |
03/02/2025 | 03/02/2025 |
| Klima Thomas J O |
7.39 USD |
122 Sold |
902 USD |
03/02/2025 | 03/02/2025 |
| Colvin Richard A CMO |
7.39 USD |
64 Sold |
473 USD |
03/02/2025 | 03/02/2025 |
| Vittiglio Joseph CLO |
7.39 USD |
238 Sold |
1,759 USD |
03/02/2025 | 03/02/2025 |
| Obenshain Andrew CEO |
9.24 USD |
140 Sold |
1,294 USD |
06/01/2025 | 06/01/2025 |
| Colvin Richard A CMO |
9.24 USD |
19 Sold |
176 USD |
06/01/2025 | 06/01/2025 |
| Obenshain Andrew CEO |
0.42 USD |
971 Sold |
405 USD |
10/12/2024 | 10/12/2024 |